Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH)’s stock price has decreased by -17.28 compared to its previous closing price of 1.91. However, the company has seen a -19.80% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-07 that CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a webcasted presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.
Is It Worth Investing in Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) Right Now?
The stock has a 36-month beta value of -0.13. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RVPH is 39.69M, and at present, short sellers hold a 14.22% of that float. On January 15, 2025, the average trading volume of RVPH was 2.50M shares.
RVPH’s Market Performance
The stock of Reviva Pharmaceuticals Holdings Inc (RVPH) has seen a -19.80% decrease in the past week, with a -43.87% drop in the past month, and a 29.51% gain in the past quarter. The volatility ratio for the week is 18.28%, and the volatility levels for the past 30 days are at 17.64% for RVPH. The simple moving average for the past 20 days is -13.20% for RVPH’s stock, with a -1.92% simple moving average for the past 200 days.
Analysts’ Opinion of RVPH
Many brokerage firms have already submitted their reports for RVPH stocks, with ROTH MKM repeating the rating for RVPH by listing it as a “Buy.” The predicted price for RVPH in the upcoming period, according to ROTH MKM is $12 based on the research report published on September 20, 2023 of the previous year 2023.
The Benchmark Company, on the other hand, stated in their research note that they expect to see RVPH reach a price target of $17. The rating they have provided for RVPH stocks is “Speculative Buy” according to the report published on June 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to RVPH, setting the target price at $10 in the report published on January 24th of the previous year.
RVPH Trading at 2.83% from the 50-Day Moving Average
After a stumble in the market that brought RVPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.29% of loss for the given period.
Volatility was left at 17.64%, however, over the last 30 days, the volatility rate increased by 18.28%, as shares sank -42.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.80% upper at present.
During the last 5 trading sessions, RVPH fell by -19.80%, which changed the moving average for the period of 200-days by -59.49% in comparison to the 20-day moving average, which settled at $1.8200. In addition, Reviva Pharmaceuticals Holdings Inc saw -12.71% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RVPH
The total capital return value is set at 3.48. Equity return is now at value -1806.28, with -512.93 for asset returns.
Based on Reviva Pharmaceuticals Holdings Inc (RVPH), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -401.44. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is 5205.61.
Currently, EBITDA for the company is -39.5 trillion with net debt to EBITDA at 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.39.
Conclusion
To sum up, Reviva Pharmaceuticals Holdings Inc (RVPH) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
